Driving the mission
The Coherence team operates where neurotechnology, biology, and AI converge. We create systems that decode the body’s bioelectronic language and turn it into actionable insight, enabling precise, adaptive interventions that disrupt cancer at its source.
Our story
Coherence is the brainchild of our co-founders, Dr. Ben Woodington and Dr. Elise Jenkins, who met in 2018 while carrying out research across the fields of neuroengineering and neuro-oncology at the University of Cambridge.
They believe that the world is at an inflection point: that the miniaturization of neuroelectronics, a step change in compute and AI, and new powering methods are going to dramatically extend the use of therapeutic BCI technologies. Bringing them into wider usage across hundreds of diseases and disorders.
“Treating and monitoring my patients, in real time, will revolutionise my practice”
Dr Ryan Mathew [Neurosurgeon]
Prof at Leeds, Principal Investigator for NIHR clinical trials
2022
Coherence is born
2023
Develops first implants to measure and modulate brain tumors in real time
2023
Discovered first neural biomarkers of cancer progression and aggression
2023
First safety study of SOMA-1
2024
Launched first pipeline indication in pancreatic cancer
2025
Expanded company to US, launching SF office and in vivo facility for pipeline expansion
Leadership
Ben is a chemist turned engineer who previously developed smart nebulizers for Phillips and led development of the first intelligent drug delivery technologies at Vectura. He completed his PhD in the lab of bioelectronics and materials science pioneer, Professor George Malliaras, at the University of Cambridge. His research focused on flexible spinal cord and brain interfaces. It was during this time that he met Elise, which led to the inception of Coherence in 2023.
Ben Woodington, PhD
Co-founder & CEO
.png)
Elise is an electrical engineer who also completed her PhD under Professor George Malliaras at the University of Cambridge. During that time, she focused on the electrical characteristics of cancer, bridging distant scientific fields that would inspire her to invent a new way to approach cancer. Previously, she designed sensors for F1 race cars and led technical teams at Siemens.
Elise Jenkins, PhD
Co-founder & CTO
José is a mechanical engineer by training. He was previously Head of Product Development at Iota Biosciences (acquired by Astellas), and has brought multiple technologies to the clinic via Abbott and Setpoint Medical.
José Lepe
VP Engineering
Jason is a neuroscientist by training who previously led translation for Google x GlaxoSmithKline collaboration, Galvani Bioelectronics. Prior to that he focused on neuro research at Pfizer.
Jason Miranda, PhD
Director Translation
Spotlight
Joshua Bratsch-Prince, PhD
Research Scientist
.png)
Carolina Silveira, PhD
Quality and Regulatory Specialist
Isabel Dziuba
Engineer II
.png)
Jake Stroud, PhD
Data & AI Lead
Advisory team
.png)
Prof George Malliaras, FRS
Prof of Bioelectronics at Cambridge University (fmr. IBM, Cornell)
.png)
Dr Ryan Mathew , PhD, FRCS
Neurosurgeon, Prof at Leeds, Principal Investigator for NIHR clinical trials
.png)
Prof Anne Vanhoestenburge
Prof of Implantable Medical Devices & Director of MAISI institute
.png)
Ryan Neely, PhD
VP Science, Elemind (fmr. Iota, Known Medicine)
Dr Andrew Morokoff
A/Prof Surgery Royal Melbourne Hospital, Clinical BCI pioneer
Brought to you by world-leading researchers, engineers, and scientists united by our mission.
